BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29904919)

  • 1. LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling.
    Liu G; Yuan D; Sun P; Liu W; Wu PF; Liu H; Yu GY
    J Cell Physiol; 2018 Nov; 233(11):8639-8647. PubMed ID: 29904919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
    Zhang Y; Cheng H; Li W; Wu H; Yang Y
    Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
    Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F
    J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
    Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
    Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis.
    Liu ZB; Wang JA; Lv RQ
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1418-1427. PubMed ID: 30840262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.
    Jin R; Jin YY; Tang YL; Yang HJ; Zhou XQ; Lei Z
    Oncol Rep; 2018 Jun; 39(6):3034-3040. PubMed ID: 29620278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Sun H; Yin M; Qian W; Yin H
    Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA LINC00968 acts as oncogene in NSCLC by activating the Wnt signaling pathway.
    Wang Y; Zhou J; Xu YJ; Hu HB
    J Cell Physiol; 2018 Apr; 233(4):3397-3406. PubMed ID: 28926089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.
    Zhang D; Wang S; Chen J; Liu H; Lu J; Jiang H; Huang A; Chen Y
    Int J Oncol; 2017 May; 50(5):1513-1530. PubMed ID: 28339091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
    Huang YK; Kang WM; Ma ZQ; Liu YQ; Zhou L; Yu JC
    Carcinogenesis; 2019 Apr; 40(2):370-379. PubMed ID: 30371738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
    Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
    Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zhu J; Lv J; Chen J; Zhang X; Ji Y
    Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
    [No Abstract]   [Full Text] [Related]  

  • 15. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.
    Yang W; Shan Z; Zhou X; Peng L; Zhi C; Chai J; Liu H; Yang J; Zhang Z
    Cancer Biomark; 2018; 23(4):589-601. PubMed ID: 30475755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of long non-coding RNA LINC00982 suppresses cell proliferation and tumor growth of papillary thyroid carcinoma through PI3K-ATK signaling pathway.
    Xu D; Yu J; Zhuang S; Zhang S; Hong Z; Yuan C
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathway.
    Wang Y; Kuang H; Xue J; Liao L; Yin F; Zhou X
    Biomed Pharmacother; 2017 Sep; 93():1230-1237. PubMed ID: 28738539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.